To assess membrane expression of DR4 and DR5 in the normal endometrium (NE), endometrial atypical hyperplasia (EAH) and endometrioid endometrial cancer (EEC), the study examined 101 patients: 20 NE, 14 EAH and 67 EEC. The expression of DR4 and DR5 was examined and presented as the total score (TS). DR4 expression was seen in 18 NE, 11 EAH and 10 EEC. DR5 expression was seen in 20 NE, 13 EAH and 21 EEC. A strong correlation between type of endometrial tissue and TS of both receptors was identified. In EEC TS of DR4 and DR5 was not related to grading, staging or survival. Malignant transformation in the endometrium is related to reduction of membrane DR4 and DR5 expression. The level of membrane staining of the receptors in EEC is not dependent on grading and staging, and is not sufficient to predict survival in EEC patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/01443615.2013.790886 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MOTS-c relieves hepatocellular carcinoma resistance to TRAIL-induced apoptosis under hypoxic conditions by activating MEF2A.
Exp Cell Res
January 2025
Hypoxia and Health Medicine Research Center, Jilin Medical University, Jilin 132013, Jilin Province, PR China. Electronic address:
Background: Mitochondrial ORF of the 12S rRNA type-c (MOTS-c) as an AMPK agonist can regulate the expression of adaptive nuclear genes to promote cell homeostasis. However, the investigation of MOTS-c in hepatocellular carcinoma (HCC) is insufficient. This study aims to reveal the role of MOTS-c on HCC cell apoptosis.
View Article and Find Full Text PDFInhibition of Chk1 with Prexasertib Enhances the Anticancer Activity of Ciclopirox in Non-Small Cell Lung Cancer Cells.
Cells
October 2024
Department of Hematology and Oncology, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.
Lung cancer is a leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most prevalent lung cancer subtype. Ciclopirox olamine (CPX), an off-patent fungicide, has been identified as a new anticancer agent.
View Article and Find Full Text PDFCisplatin-encapsulated TRAIL-engineered exosomes from human chorion-derived MSCs for targeted cervical cancer therapy.
Stem Cell Res Ther
November 2024
Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, No. 109 Xueyuan Xi Road, Wenzhou, Zhejiang, 325027, China.
Article Synopsis
- Cisplatin (DDP) is a common chemotherapy drug used for treating cervical cancer, particularly in advanced cases or for patients wishing to preserve fertility; TRAIL is a protein that can selectively induce death in cancer cells.
- Human chorion-derived mesenchymal stem cells (hCD-MSCs) were modified to enhance TRAIL production and their exosomes (hCD-MSCs-Exo) were developed as delivery vehicles for DDP via a method called electroporation.
- The combination of DDP and hCD-MSCs-Exo demonstrated improved effectiveness in reducing cancer cell proliferation and promoting apoptosis in vitro and in vivo, with minimal toxicity, indicating a promising therapeutic approach for cervical cancer treatment.
Oncolytic avian reovirus-sensitized tumor infiltrating CD8 T cells triggering immunogenic apoptosis in gastric cancer.
Cell Commun Signal
October 2024
Institute of Molecular Biology, National Chung Hsing University, Taichung, 402, Taiwan.
Background: Gastric cancer (GC) is a leading malignant disease in numerous countries, including Taiwan with limited therapeutic options. Animal viruses including oncolytic avian reovirus (ARV) have the possibility to avoid pre-existing immunity in humans, while being safe and immunostimulatory. Here, we provide a novel insight into oncolytic ARV and UV-ARV-sensitized patient's peripheral blood mononuclear cells (P-PBMCs) and tumor infiltrating lymphocytes (TILs) killing primary GC (PGC) cells through the surface TLR3 and TRAIL/DR4/DR5 immunogenic apoptosis pathway.
View Article and Find Full Text PDFStudy of TRAIL and SAHA Co-Treatment on Leukemia K562 Cell Line.
Cell Biochem Biophys
October 2024
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand) is an attractive agent being considered a potential cancer treatment. It attaches to its death receptors, leading many cancer cells to apoptosis. However, some malignancies indicate substantial resistance to TRAIL, challenging anticancer scientists.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!